Treatment of Hypertension in New Frontiers

This symposium took place on 30th August 2015 as a part of the European Society of Cardiology (ESC) Congress in London, UK

Co-Chairs: Bryan Williams,1 Gordon Thomas McInnes2
Speakers: Bryan Williams,1 Gordon Thomas McInnes,2 Jesús Isea-Pérez,3 Jorge Sison4

1. University College London (UCL), London, UK
2. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
3. Fundación Venezolana de Cardiología Preventiva, Caracas, Venezuela
4. Medical Centre Manila, Manila, Philippines

Disclosure: Bryan Williams received speaker fees from Boehringer Ingelheim, Daiichi, Novartis, Pfizer, and Sankyo. Gordon Thomas McInnes received research grants, consultation fees, and speaker honoraria from Bayer, Boehringer Ingelheim, Novartis, Pfizer, and Takeda. Jesús Isea-Pérez participated in meetings, received speaker and advisory board honoraria, and received research/educational grants from AstraZeneca, Bayer, Novartis, Pfizer, and Sanofi-Aventis. Jorge Sison received speaker honoraria from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK), Novartis, and Pfizer, and received professional fees as principal investigator from GSK and Merck.
Acknowledgements: Writing assistance was provided by Dr Ana Rodríguez de Ledesma (ApotheCom).
Support: The symposium was jointly organised and funded by Novartis Pharmaceuticals. All authors received honoraria for preparation and delivery of their presentations. The publication of this article was funded by Novartis Pharmaceuticals. The paper is an interpretation of the views of the speakers, but is not written by them. The views and opinions expressed are those of the authors and not necessarily of Novartis Pharmaceuticals.
Citation: EMJ Cardiol. 2015;3[2]:44-52.

Meeting Summary

This symposium provided an excellent forum in which to discuss the global burden of hypertension (HTN), its challenges, and approaches to best management in new frontiers. The symposium speakers also reviewed recent data for clinical practice, especially those relevant for patients at high risk of HTN. The presentations were delivered within a highly interactive setting to facilitate audience questions and discussion.

The symposium was opened by Prof Bryan Williams, who gave a description of the global burden of HTN, emphasising the need for effective, simplified treatment strategies and algorithms to effectively control blood pressure (BP). Prof Gordon Thomas McInnes then gave an overview of the challenges faced when treating HTN in the developing world and the best management practices of HTN adopted across different countries. HTN control in Latin America (LA) and the Caribbean region, and its opportunities and challenges was the subject of the next presentation given by Dr Jesús Isea-Pérez. Lastly, Dr Jorge Sison discussed HTN control in Asia and the Middle East, presenting real-world data in addition to a review of the latest clinical data on optimal management of HTN, and focussing on the use of single-pill combination (SPC) therapies. This engaging and interactive symposium was facilitated by multiplechoice questions posed by speakers, allowing audience participation via an electronic voting system. The meeting closed with a lively panel discussion and concluding remarks from Prof Bryan Williams.

This truly international symposium brought together more than 550 delegates from across Europe and North America, Africa and the Middle East, Asia and Pacific regions, and Central and South America, with attendees representing a wide range of clinical and professional settings.

Would you like to see the webcast? Please click here and register for free access.

Download (PDF, 259KB)

Comments are closed.